Paper Details

  1. Home
  2. Paper Details

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Author: , AdroverEncarna, AlbaEmilio, AlmenarSergio, AlvarezIsabel, AlvarezJosé Valero, AntónAntonio, ArandaEnrique, BaenaJosé Manuel, CalvoLourdes, CrespoCarmen, García PucheJosé Luis, GonzalezSonia, González-PalaciosJesús Fernando, Gracia MarcoJose Manuel, GuitiánMaría Dolores, LluchAna, López García-AsenjoJosé Antonio, López-VegaJosé Manuel, MartínMiguel, MayordomoJosé Ignacio, MelJose Ramón, ModolellAlfonso, MunárrizBlanca, PalaciosJosé, PelegríAmadeu, PlazaolaArrate, RamosManuel, RodríguezCésar A, Rodríguez-LescureAlvaro, RuizAmparo, Ruiz-BorregoManuel, SeguíMiguel Angel, Sánchez-RoviraPedro, VeraFrancisco, de AlavaEnrique

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 1246 women with breast cancer found that adding paclitaxel to standard chemotherapy significantly reduced the risk of the cancer returning.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting. METHODS: After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluoro...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jnci/djn151

データ提供：米国国立医学図書館（NLM）

FEC-P Therapy: A Promising Treatment for Early Breast Cancer

The vast and often unforgiving landscape of [breast cancer] treatment is constantly evolving. This research explores the efficacy of [FEC-P], a combination chemotherapy regimen, in the adjuvant setting for early breast cancer. This [randomized phase 3 trial] compared the effectiveness of FEC-P to standard [FEC] therapy. The results show that FEC-P, with its addition of [paclitaxel], significantly reduced the risk of relapse and death, providing a beacon of hope for patients with lymph node-positive breast cancer.

FEC-P: A Statistically Significant Improvement in Disease-Free Survival

The study, a true oasis in the desert of breast cancer research, found that FEC-P demonstrated a statistically significant improvement in disease-free survival compared to FEC. This means that patients treated with FEC-P were less likely to experience a recurrence of their cancer. These findings are truly encouraging, offering patients a new avenue for treatment and potentially improving long-term outcomes.

FEC-P and Breast Cancer Treatment: A Camel's Take

It's important to remember that every patient's journey with breast cancer is unique. This study provides valuable insight into the potential benefits of FEC-P for early breast cancer, but it's always important to discuss treatment options with your doctor and make informed decisions.

Dr.Camel's Conclusion

This study highlights the potential of FEC-P as a valuable adjuvant treatment for early breast cancer, offering a significant reduction in relapse risk and mortality. The findings provide new hope for patients seeking effective treatment options. While FEC-P shows great promise, it's essential to consult with a medical professional and explore all available treatment options.

Date :
  1. Date Completed 2008-07-02
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

18505968

DOI: Digital Object Identifier

10.1093/jnci/djn151

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.